Table 5. Correlations between CTC and molecular expression in LUSC.
| Molecular expression | Negative, N (%) | Positive, N (%) | Unknown, N (%) | Clinical information | P |
|---|---|---|---|---|---|
| TTF-1 (10%) | 1,127 (50.63) | 646 (29.02) | 453 (20.35) | −0.200 | 0.28 |
| Calretinin (5%) | 83 (3.73) | 36 (1.62) | 2,107 (94.65) | −0.004 | 0.98 |
| CD34 (20%) | 91 (4.09) | 39 (1.75) | 2,096 (94.16) | −0.115 | 0.55 |
| CD56 (5%) | 98 (4.40) | 43 (1.93) | 2,085 (93.67) | 0.145 | 0.44 |
| CD68 (30%) | 137 (6.15) | 209 (9.39) | 1,880 (84.46) | −0.156 | 0.40 |
| CDX2 (50%) | 61 (2.74) | 26 (1.17) | 2,139 (96.09) | −0.189 | 0.31 |
| c-MET (25%) | 37 (1.66) | 45 (2.02) | 2,144 (96.32) | 0.179 | 0.34 |
| CgA (10%) | 53 (2.38) | 40 (1.80) | 2,133 (95.82) | −0.042 | 0.83 |
| CK (10%) | 767 (34.46) | 1,044 (46.90) | 415 (18.64) | 0.148 | 0.43 |
| CK20 (10%) | 198 (8.89) | 210 (9.43) | 1,818 (81.67) | 0.039 | 0.84 |
| CK7 (10%) | 29 (1.30) | 288 (12.94) | 1,909 (85.76) | 0.233 | 0.21 |
| CK8/18 (10%) | 10 (0.45) | 213 (9.57) | 2,003 (89.98) | −0.691 | 0.03 |
| Desmin (1%) | 176 (7.91) | 17 (0.76) | 2,033 (91.33) | −0.060 | 0.75 |
| E-cadherin (25%) | 117 (5.26) | 63 (2.83) | 2,046 (91.91) | 0.099 | 0.60 |
| ER (25%) | 112 (5.03) | 48 (2.16) | 2,066 (92.81) | 0.304 | 0.10 |
| GATA3 (50%) | 71 (3.19) | 834 (37.47) | 1,321 (59.34) | 0.026 | 0.89 |
| GATA6 (10%) | 344 (15.45) | 402 (18.06) | 1,480 (66.49) | 0.655 | 0.03* |
| GPA33 (1%) | 79 (3.55) | 92 (4.13) | 2,056 (92.36) | 0.170 | 0.36 |
| HER2 (50%) | 101 (4.54) | 279 (12.53) | 1,846 (82.93) | −0.006 | 0.98 |
| HNF4α (1%) | 49 (2.20) | 178 (8.00) | 1,999 (89.80) | −0.002 | 0.99 |
| Ki-67 (25%) | 146 (6.56) | 514 (23.09) | 1,566 (70.35) | 0.214 | 0.25 |
| LCA (10%) | 57 (2.56) | 74 (3.32) | 2,095 (94.12) | −0.046 | 0.81 |
| MTAP (50%) | 38 (1.71) | 20 (0.90) | 2,168 (97.39) | 0.559 | 0.047* |
| MUC4 (5%) | 18 (0.81) | 55 (2.47) | 2,153 (96.72) | 0.169 | 0.37 |
| Napsin A (25%) | 376 (16.89) | 967 (43.44) | 883 (39.67) | 0.154 | 0.24 |
| P40 (10%) | 140 (6.29) | 1,984 (89.13) | 102 (4.58) | 0.066 | 0.73 |
| P53 (50%) | 702 (31.54) | 1,330 (59.75) | 194 (8.72) | 0.270 | 0.14 |
| Pou2F3 (1%) | 154 (6.92) | 53 (2.38) | 2,019 (90.70) | 0.055 | 0.77 |
| PD-L1 (1%) | 543 (24.39) | 1,263 (56.74) | 420 (18.87) | −0.012 | 0.95 |
| PR (5%) | 21 (0.94) | 47 (2.11) | 2,158 (96.95) | −0.101 | 0.59 |
| SALL4 (25%) | 663 (29.78) | 1,116 (50.13) | 447 (20.08) | 0.177 | 0.34 |
| SMARCA4 (25%) | 418 (18.78) | 1,456 (65.41) | 352 (15.81) | 0.178 | 0.35 |
| Villin (10%) | 164 (7.37) | 23 (1.03) | 2,039 (91.60) | −0.089 | 0.63 |
| WT-1 (1%) | 70 (3.14) | 89 (4.00) | 2,067 (92.86) | 0.080 | 0.67 |
| ZEB1 (10%) | 528 (23.72) | 451 (20.26) | 1,247 (56.02) | −0.093 | 0.62 |
| β-catenin (50%) | 111 (4.99) | 742 (33.33) | 1,373 (61.68) | 0.215 | 0.25 |
For molecular expression, the percentage in parentheses represents the threshold for positive and negative expressions. *, P<0.05. CTC, circulating tumor cell; LUSC, lung squamous cell carcinoma; TTF-1, thyroid transcription factor-1; CK, cytokeratin; C-MET, cellular-mesenchymal to epithelial transition factor; LCA, leucocyte common antigen; MTAP, methylthioadenosine phosphorylase; ER, estrogen receptor; PD-L1, programmed cell death ligand 1; PR, progesterone receptor; SALL4, spalt-like transcription factor 4; SMARCA4, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin; WT-1, Wilms tumor 1; ZEB1, zinc finger E-box binding homeobox 1.